Sunitinib, a tyrosine kinase inhibitor, has been approved by the FDA for the treatment of kidney cancer and stromal gastrointestinal cancer, but its effectiveness in melanoma was unknown until this study.
Several factors, including sporting activity, physical workload, and smoking habits, affect the sonomorphologic characteristics of peripheral lymph nodes (LNs) in patients with a history of invasive cutaneous melanoma.
Experts tell Chemotherapy Advisor that new consumer-targeted cancer-screening apps may put patients at risk.
A minimal, less-toxic conditioning treatment with cyclophosphamide, which allows cytotoxic T-lymphocyte clones to survive for longer, shows some clinical benefit in patients with refractory, metastatic melanoma.
Melanoma patients may have received a shot of life today with news that a vaccine for the deadly cancer has received FDA clearance for Phase 3 clinical testing.
Retinol supplementation is associated with a lower risk of melanoma.
Data from the Nurses’ Health Study II (NHSII) cohort confirm a dose-response relationship between tanning bed use and risk of the three most common types of skin cancer, according to a study in the Journal of Clinical Oncology published online February 27.
Presence of 0.001 to 2.0 dermatologists per 100,000 people reduces melanoma mortality.
The oral BRAF inhibitor vemurafenib (PLX4032; Zelboraf) induced a high rate of response in patients with previously treated BRAF V600-mutant metastatic melanoma, with a median overall survival nearly twice that currently observed, according to results of a multicenter Phase 2 trial.
Chronic leg ulcers (CLUs) that don’t heal after three months of appropriate treatment have an overall skin cancer frequency of 10.4%.
